Trial Profile
Safety and Tolerability of Tumor Treating Fields (TTFields) Combined With Chemoradiation in Newly Diagnosed Glioblastoma (Unity)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- Acronyms Unity
- 11 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2020 Status changed from not yet recruiting to recruiting.
- 26 Nov 2019 Planned initiation date changed from 1 Nov 2019 to 2 Dec 2019.